Related Experiment Video

Updated: May 11, 2026

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

Response to 'Red blood cell distribution width is a predictor of readmission in cardiac patients'

Sevket Balta, Sait Demirkol, Omer Kurt

    Clinical Cardiology
    |May 17, 2013
    PubMed
    Abstract

    No abstract available in PubMed .

    Related Experiment Videos

    Last Updated: May 11, 2026

    Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
    05:16

    Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

    Published on: June 10, 2025

    Related Concept Videos

    Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

    Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

    Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
    These markers indicate stress or strain on the heart muscle:
    Natriuretic Peptides (BNP)
    Cardiac myocytes produce these hormones in response to ventricular stretching...

    Articles linked to this work by shared authors, journal, and citation graph.

    Ezetimibe therapy for dyslipidemia: an update.

    Current pharmaceutical design·2013

    The role of fibrate treatment in dyslipidemia: an overview.

    Current pharmaceutical design·2013

    Combined dyslipidemia: should the focus be LDL cholesterol or atherogenic dyslipidemia?

    Current pharmaceutical design·2013

    PCSK9 inhibition - a novel mechanism to treat lipid disorders?

    Current pharmaceutical design·2013

    Hydrochlorothiazide vs. chlorthalidone as the optimal diuretic for the management of hypertension.

    Current pharmaceutical design·2013

    Pioglitazone and cancer: angel or demon?

    Current pharmaceutical design·2013

    Antithrombotic Therapy in Coronary Artery Aneurysm, Ectasia, and Slow Flow: A Systematic Review.

    Clinical cardiology·2026

    Long-Term Renal Function and Clinical Outcomes of Sacubitril/Valsartan in HFrEF and Stage 3-4 Chronic Kidney Disease: A 24-Month Single-Centre Cohort.

    Clinical cardiology·2026

    Outcomes of an Interventional Approach in STEMI and NSTEMI All-Comer Octo and Nonagenarians.

    Clinical cardiology·2026

    Targeted Superior Vena Cava Isolation Combined With Pulmonary Vein Isolation Versus Pulmonary Vein Isolation Alone Using Cryoballoon Ablation for Atrial Fibrillation.

    Clinical cardiology·2026

    Closed-Loop AI Systems for Arrhythmia Management: Toward Predictive, Personalized, and Safe Cardiac Care.

    Clinical cardiology·2026

    Prospective Evaluation of Quality-of-Life Improvement After Dapagliflozin Initiation in a Greek Population With HFrEF: The EVOLUTION-HF 12-Month Results.

    Clinical cardiology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us